The present disclosure features compositions and methods for the treatment of bacterial infections, such as bacterial infections caused by bacterial cells residing within a host cell (e.g., a mammalian cell, e.g., immune cell, e.g., macrophage or dendritic cell). The compositions and methods include delivering a bacteriophage and an antibacterial lytic protein to the intracellular computment (endosome, phagosome, lysosome, or cytosol) in which the bacterial cell resides.

The present disclosure features compositions and methods for the treatment of bacterial infections, such as bacterial infections caused by bacterial cells residing within a host cell (e.g., a mammalian cell, e.g., immune cell, e.g., macrophage or dendritic cell). The compositions and methods include delivering a bacteriophage and an antibacterial lytic protein to the intracellular computment (endosome, phagosome, lysosome, or cytosol) in which the bacterial cell resides.

Bone mineral content, 25(OH) vitamin D3, or 1,25(OH).sub.2 vitamin D3 in a companion animal can be improved by adjusting the diet of the animal to increase the amount of a compound which positively or negatively modulates the bone mineral content, 25(OH) vitamin D3, or 1,25(OH).sub.2 vitamin D3 or adjusting the diet of the animal to decrease the amount of a compound which positively or negatively modulates the bone mineral content, 25(OH) vitamin D3, or 1,25(OH).sub.2 vitamin D3.

Bone mineral content, 25(OH) vitamin D3, or 1,25(OH).sub.2 vitamin D3 in a companion animal can be improved by adjusting the diet of the animal to increase the amount of a compound which positively or negatively modulates the bone mineral content, 25(OH) vitamin D3, or 1,25(OH).sub.2 vitamin D3 or adjusting the diet of the animal to decrease the amount of a compound which positively or negatively modulates the bone mineral content, 25(OH) vitamin D3, or 1,25(OH).sub.2 vitamin D3.

Disclosed is use of a composition for preventing and/or eliminating platelet aggregation in an in vitro blood sample. The composition comprises at least one compound selected from the group consisting of formula, R1-NH—R2, and a salt thereof. Also disclosed is an agent, which comprises the compound for reducing platelet aggregation interference in an in vitro blood test, and a method for preventing and/or eliminating platelet aggregation in a sample in an in vitro blood test. The compound of the present invention exhibits a disaggregation effect in multiple types of platelet aggregation circumstances, and the platelet disaggregation takes effect within a short time without additional conditions such as temperature control with water bath, prolonged reaction time and the like, thereby eliminating platelet aggregation in a sample conveniently and thus accurate blood cell detection parameters can be obtained.

The invention provides pharmaceutical compositions of caspase inhibitor(s), apoptosis inducer(s), and/or PD-1 pathway inhibitor(s), and methods for treating cancer and related diseases and conditions.

The invention provides pharmaceutical compositions of caspase inhibitor(s), apoptosis inducer(s), and/or PD-1 pathway inhibitor(s), and methods for treating cancer and related diseases and conditions.

The present invention relates to a pharmaceutical composite composition for prevention or treatment of diabetes mellitus and at least one disease selected from metabolic diseases associated therewith. The pharmaceutical composition according to the present invention exhibits excellent effects of lowering blood glucose levels, body weight, and blood lipid levels. Therefore, the composition can be advantageously used for preventing or treating diabetes mellitus and at least one disease selected from metabolic diseases associated therewith.

The present invention relates to a pharmaceutical composite composition for prevention or treatment of diabetes mellitus and at least one disease selected from metabolic diseases associated therewith. The pharmaceutical composition according to the present invention exhibits excellent effects of lowering blood glucose levels, body weight, and blood lipid levels. Therefore, the composition can be advantageously used for preventing or treating diabetes mellitus and at least one disease selected from metabolic diseases associated therewith.

Monoethanolamine (Etn) displays strong in vitro and in vivo efficacy in prostate cancer cell lines and xenograft models, respectively, as well as in cell lines from diverse cancer types. Etn is a pro-drug, which upon entry into tumor cells, is converted into cytotoxic phosphoethanolamine (PhosE). Etn treatment potently down-regulates HIF-1α and drives a catastrophic uncoupling of multiple pathways to induce metabolic crisis and cell death, selectively in tumor cells, while sparing normal cells. Importantly, the ovarian cancer cell line OVCAR3 was more sensitive to Etn than all the prostate, breast, colon, and pancreatic cancer cell lines tested. An Etn-based formulation with favorable pharmacokinetics/pharmacodynamics (PK/PD) can therefore in some embodiments be used as single therapeutic for EOC or OCCC.